Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate

ClinicalTrials.gov ID: NCT01426438

Public ClinicalTrials.gov record NCT01426438. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 3:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Effect of HDL-Raising Therapies on Endothelial Function, Lipoproteins, and Inflammation in HIV-infected Subjects With Low HDL Cholesterol: A Phase II Randomized Trial of Extended Release Niacin vs. Fenofibrate

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is being done with people with HIV infection who have low levels of HDL-C. HDL-C is a type of "good" cholesterol. People with low HDL-C have a higher risk of heart disease and may have problems with how their blood vessels relax. The endothelium is the inner lining of all blood vessels, such as arteries and veins. When the endothelium is not working properly, the blood vessels have trouble expanding properly, which contributes to the development of heart and blood vessel disease. The main purpose of this study is to see if taking either extended-release niacin or fenofibrate for 24 weeks will help blood vessels work better by improving endothelial function and increasing HDL-C. Niacin and fenofibrate are medications that raise HDL-C. This study will also help determine how safe extended-release niacin and fenofibrate are. The analysis is an as-treated analysis of participants who completed study treatment and had a week 24 BART scan. Safety analyses include all participants

Study identification

NCT ID
NCT01426438
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
99 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2011
Primary completion
Sep 30, 2013
Completion
Sep 30, 2013
Last update posted
Feb 2, 2016

2011 – 2013

United States locations

U.S. sites
14
U.S. states
9
U.S. cities
13
Facility City State ZIP Site status
Alabama Therapeutics CRS (5801) Birmingham Alabama 35294
University of Southern California (1201) Los Angeles California 90033-1079
UCLA CARE Center CRS (601) Los Angeles California 90095
Harbor-UCLA Med. Ctr. CRS (603) Torrance California 90502
University of Colorado Hospital CRS (6101) Aurora Colorado 80045
Northwestern University CRS (2701) Chicago Illinois 60611
New Jersey Medical School-Adult Clinical Research Ctr. CRS (31477) Newark New Jersey 07103
NY Univ. HIV/AIDS CRS (401) New York New York 10016
Unc Aids Crs (3201) Chapel Hill North Carolina 27516
Duke Univ. Med. Ctr. Adult CRS (1601) Durham North Carolina 27710
Moses H. Cone Memorial Hospital CRS (3203) Greensboro North Carolina 27401
Univ. of Cincinnati CRS (2401) Cincinnati Ohio 45267
Case CRS (2501) Cleveland Ohio 44106
University of Washington AIDS CRS (1401) Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01426438, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 2, 2016 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01426438 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →